Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries NRX Pharmaceuticals, Inc. - Common Stock (NQ: NRXP ) 1.510 -0.020 (-1.31%) Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 466,617 Open 1.550 Bid (Size) 1.480 (10) Ask (Size) 1.530 (9) Prev. Close 1.530 Today's Range 1.410 - 1.560 52wk Range 1.100 - 7.333 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Jonathan Javitt, CEO of NRx Pharmaceuticals Inc. (NASDAQ: NRXP), to Present at NobleCon20 November 13, 2024 Via Investor Brand Network HOPE Therapeutics Secures Financing For Ketamine Clinic Expansion August 26, 2024 HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), Via Benzinga Performance YTD -69.74% -69.74% 1 Month +17.05% +17.05% 3 Month -13.71% -13.71% 6 Month -38.11% -38.11% 1 Year -67.46% -67.46% More News Read More Plans for New Acquisition of Clinics Generating $100 Million to Complement Progress on Accelerated Drug Approval for Bipolar Depression and Related Disorders: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) August 26, 2024 Via Get News Topics Regulatory Compliance Exposures Legal Regulatory Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) August 15, 2024 Via Get News Topics Regulatory Compliance Retirement Exposures Legal Pension Regulatory NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q2 2024 August 14, 2024 Via InvestorPlace Alignment with FDA on Pediatric Study Plan and Accelerated Approval to Treat Bipolar Depression and Akathisia: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) July 30, 2024 Via Get News Exposures Product Safety Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: Nasdaq: NRXP August 15, 2024 Via PRLog Topics Regulatory Compliance Exposures Legal Product Safety Regulatory Accelerated Approval to Treat Bipolar Depression and Akathisia Could Yield Over $150 in Revenue Per Share; Planned HOPE Subsidiary Spinoff to Continue: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) July 29, 2024 Via Get News NRx Pharmaceuticals Highlights Breakthrough Oral Antidepressant’s Efficacy in Reducing Suicidality in Bipolar Depression at ASCP June 2024 Meeting: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) June 10, 2024 Via Get News First Oral Antidepressant Clinically Demonstrated to Reduce Suicidality in Bipolar Depression with Data Supporting Accelerated Approval Process: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) May 28, 2024 Via Get News 12 Health Care Stocks Moving In Thursday's Intraday Session May 16, 2024 Via Benzinga NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q1 2024 May 14, 2024 Via InvestorPlace NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update May 08, 2024 Via ACCESSWIRE Final Clinical Trial Results Show Superior Safety and Efficacy for NRX-101; Plans to Seek Accelerated Approval for Bipolar Depression and Schizophrenia: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) May 06, 2024 Via Get News 12 Health Care Stocks Moving In Monday's Intraday Session May 06, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session May 01, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session April 30, 2024 Via Benzinga Gold Down Over 2%; 3M Profit Beats Expectations April 30, 2024 Via Benzinga Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session April 30, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session April 30, 2024 Via Benzinga Why Is NRx Pharmaceuticals Stock Falling After Data From Suicidal Bipolar Depression Study April 30, 2024 Via Benzinga InvestorNewsBreaks – NRx Pharmaceuticals Inc. Releases Pricing of Public Offering, Expected to Result in Estimated $2M April 22, 2024 Via Investor Brand Network Exposures Product Safety Nasdaq Down 0.5%; Lithium Americas Shares Slide April 18, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session April 18, 2024 Via Benzinga Crude Oil Edges Lower; Bio-Path Holdings Shares Spike Higher April 18, 2024 Via Benzinga Exposures Fossil Fuels Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
